Methods and kits for diagnosing obstructive sleep apnea

摘要

The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.

主权项

1. A method for diagnosing obstructive sleep apnea in a subject, comprising:
(a) providing a biological sample from the subject; (b) determining an amount in the sample of a Urocortin III peptide; (c) determining an amount in the sample of a Uromodulin peptide, an Orosomucoid 1 peptide, a Kallikrein 1 peptide, or a combination thereof; (d) comparing the amount of the Urocortin III peptide in the sample, if present, to a control level of the Urocortin III peptide, (e) comparing the amount of the Uromodulin peptide, the Orosomucoid 1 peptide, the Kallikrein 1 peptide, or the combination thereof in the sample, if present, to a control level of the Uromodulin peptide, the Orosomucoid 1 peptide, the Kallikrein 1 peptide, or the combination thereof; and (f) diagnosing the subject as having obstructive sleep apnea, or a risk thereof, if there is a measurable increase in the amount of the Urocortin III peptide and if there is a measurable increase in the amount of the Uromodulin peptide, a measurable increase in the amount of the Orosomucoid 1 peptide, a measurable decrease in the amount of the Kallikrein 1 peptide, or the combination thereof in the sample as compared to the control levels, wherein determining the amount in the sample of the Urocortin III peptide and the amount in the sample of the Uromodulin peptide, the Orosomucoid 1 peptide, the Kallikrein 1 peptide, or the combination thereof comprises determining the amount in the sample using mass spectrometry (MS) analysis, immunoassay analysis, or both, wherein the mass spectrometry (MS) analysis is selected from the group consisting of liquid-chromatography mass spectrometry (LC-MS), electrospray ionization mass spectrometry (ESI-MS), matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), and surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and wherein the immunoassay analysis is selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA) and an immunoturbidimetric assay.